Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (June 2025)
22 slides from Staar Surgical's investor presentation, June 2025
Slide 1: Investor Presentation
Addressing the myopia epidemic as the global leader in phakic IOLs for vision correction NASDAQ: STAA Investor Presentation June 2025
Slide 2: Forward Looking Statements
02 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27
Slide 3: Non-GAAP Financial Information
03 Non-GAAP Financial Information To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this presentation and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses the
Slide 4: Our Innovative Technology
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 04 Our Innovative Technology EVO Preserves both the Tear Film and the Cornea Preserving the Tear Film: Does not induce dry eye1, 2 Preserving the Cornea: No tissue removal Reversible No risk of ectasia3 Rapid
Slide 5: Global Presence
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 05 Global Presence STAAR’s Geographic Sales Mix 27% Global Reach: 75+ Countries APAC ex. China 8% AMERICAS #1 refractive market share in Japan 51% 14% CHINA EMEA 12%+ refractive market share globally $313.9M
Slide 6: Strong Financial Model Positioned for Rebound
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 06 Strong Financial Model Positioned for Rebound Today Net Sales Net Sales Growth Cash, Cash Equivalents and Investments $313.9M -2.6% Y/Y $222.8M FY24 FY24 As of March 28, 2025 What’s Possible? Gross Margin
Slide 7: EVO ICL's Competitive Advantage and the Large and Growing Market Opportunity
EVO ICL’s Competitive Advantage and the Large and Growing Market Opportunity
Slide 8: Why EVO ICL is the Clear Choice in Vision Correction
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 08 Why EVO ICL is the Clear Choice in Vision Correction Traditional Vision Correction Either Limits Lifestyle or Alters the Cornea EVO ICL vs. Laser Vision Correction Procedures EVO LASIK PRK Safety Features
Slide 9: EVO ICL: The Collamer Difference
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 09 EVO ICL: The Collamer® Difference Other Lens-Based Phakic IOLs Collamer® 1 Collamer is a proprietary lens material Only created and used exclusively by STAAR® Acrylic Phakic IOLs Collamer® Phakic IOL Colla
Slide 10: EVO ICL is Capturing Share in Today's Refractive Surgery Market
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 10 10 EVO ICL is Capturing Share in Today’s Refractive Surgery Market We believe the benefits of our EVO ICL technology make it the clear choice for refractive vision correction as it has already become 5.2M
Slide 11: Our Opportunity is Much Larger than Today's Refractive Surgery Market
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 11 Our Opportunity is Much Larger than Today’s Refractive Surgery Market Broader Target Market and Opportunity Where is the Market? Patients with myopia who have Myopia by Country (Ages 21-45) Elected to Rema
Slide 12: The Transformational Opportunity
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 12 The Transformational Opportunity Today, just in elect a surgical vision correction option
Slide 13: Almost 50% of the Global Population Expected to Have Myopia by 2050
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 13 Our Market Opportunity is Growing… Almost 50% of the Global Population is Expected to Have Myopia by 2050 Myopia prevalence growing through 2050 Our opportunity is greater down the diopter curve 33% 50% -2
Slide 14: Recent Financial Results
Additive Recent Financial Results
Slide 15: First Quarter 2025 – Transition & Turnaround in Progress
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 15 First Quarter 2025 – Transition & Turnaround in Progress Net Sales Dollars in millions Gross Margin Adjusted EBITDA1 Dollars in millions $5.3 $77.4 78.9% $(26.4) 65.8% Q1 2024 Q1 2025 $42.6 Adjusted EBITDA
Slide 16: Regional Sales Growth (Ex. China) Despite Macroeconomic Headwinds
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 16 Additive Regional Sales Growth (Ex. China) Despite Macroeconomic Headwinds ($ MILLIONS) UNAUDITED Q1’25 Growth Y/Y Americas $6.2 $6.4 $6.7 Global Sales Ex. China +9% Q1 2024 Q4 2024 Q1 2025 +9% Positive gl
Slide 17: Short Term Tactical Challenges and Long Term Investment Thesis
Additive Short Term Tactical Challenges and Long Term Investment Thesis
Slide 18: Short Term Challenges Have Been Addressed
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 18 Short Term Challenges Have Been Addressed Management Transition China Inventory Complete Q2 '25 Complete Q2 '25 Streamlined management Worked with China distributors to structure to be more effective and m
Slide 19: Long Term Investment Thesis
Introduction | Technology | Markets | Financial Results | Key Imperatives | Investment Case 19 Long Term Investment Thesis Tactical Headwinds Substantially Addressed Macroeconomic Headwinds Appear to be Slowing Collamer Technology is Proven and Difficult to Replicate EVO ICL has a Long Track Record
Slide 20: Thank You
Thank You STAAR SURGICAL Nasdaq: STAA
Slide 21: Sales by Geography
Appendix 21 Sales by Geography (IN 000’S) UNAUDITED FISCAL YEAR THREE MONTHS ENDED Sales by Region 2022 2023 2024 Mar 29, 2024 Jun 28, 2024 Sep 27, 2024 Dec 27, 2024 Mar 28, 2025 Americas(1) 19,798 22,315 25,229 6,157 6,656 6,029 6,387 6,739 EMEA(2) 40,733 39,488 44,073 11,202 10,235 9,760 12,876 12
Slide 22: Reconciliation of Non-GAAP Financial Measures
Appendix 22 Reconciliation of Non-GAAP Financial Measures (IN 000’S) UNAUDITED Net Income (Loss) to Adjusted EBITDA (in 000's except for per share data) 2022 Q1-23 Q2-23 Q3-23 Q4-23 2023 Q1-24 Q2-24 Q3-24 Q4-24 2024 Q1-25 Net income (loss) (as reported) $39,665 $2,710 $6,064 $4,817 $7,756 $21,347 $(
STAAR Surgical Company — Investor Presentation (June 2025) on 6ix